SCHEMBL862083

SCHEMBL862083

N[C@H]1CC[C@@H](N2CCOCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL3 Q96JM7 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
OPRL1 P41146 2/20 0.38
ALDH1A1 P00352 3/20 0.35
CYP2A13 Q16696 1/20 0.35
HPGD P15428 1/20 0.35
IRAK4 Q9NWZ3 4/20 0.35
IRAK2 O43187 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
IRAK1 P51617 1/20 0.35
HASPIN Q8TF76 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
IRAK3 Q9Y616 1/20 0.35
HRH3 Q9Y5N1 4/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138980 1.00 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
SCHEMBL138979 1.00 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
Hydrochloric Acid SCHEMBL1699971 0.98 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
Hydrochloric Acid SCHEMBL15227231 0.98 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
Hydrochloric Acid SCHEMBL16593368 0.98 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
Hydrochloric Acid SCHEMBL1699970 0.98 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
SCHEMBL15134619 0.88 HRH3 (0.44) SMN1; SMN2HRH3
SCHEMBL3168997 0.87
SCHEMBL26112782 0.87 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB
SCHEMBL26112778 0.87 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115109032-B Quinoline derivative and application thereof in medicine 成都百裕制药股份有限公司 2023-09-05 CN disclosed
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 US disclosed
CN-115109032-A Quinoline derivative and application thereof in medicine 成都百裕制药股份有限公司 2022-09-27 CN disclosed
WO-2022194237-A1 QUINOLINE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF AUTOIMMUNE DRUG 成都百裕制药股份有限公司 2022-09-22 WO disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
EP-1778240-B1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES ONCOHEROES BIOSCIENCES INC (US) 2020-03-25 EP disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20090143379-A1 Storage stable perfusion solution for dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 US disclosed
US-20090143379-A1 Storage stable perfusion solution for dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 US disclosed
US-20080293944-A1 Piperazinyl Compounds ONCOHEROES BIOSCIENCES INC. 2008-11-27 US disclosed
US-20080293944-A1 Piperazinyl Compounds ONCOHEROES BIOSCIENCES INC. 2008-11-27 US disclosed
US-20080221099-A1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES ONCOHEROES BIOSCIENCES INC. 2008-09-11 US disclosed
US-20080221099-A1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES ONCOHEROES BIOSCIENCES INC. 2008-09-11 US disclosed
US-20080171747-A1 Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions ONCOHEROES BIOSCIENCES INC. 2008-07-17 US disclosed
US-20080171747-A1 Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions ONCOHEROES BIOSCIENCES INC. 2008-07-17 US disclosed
EP-1778238-A1 DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-02 EP disclosed
WO-2006018221-A1 DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221099-A1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES PLK4, TK1, POLK SMN1; SMN2 2175/4885L3MBTL3 3832/4885L3MBTL1 3208/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885
US-20090143379-A1 Storage stable perfusion solution for dihydropteridinones QDPR, F5, F12 SMN1; SMN2 2653/4885L3MBTL3 4268/4885L3MBTL1 3936/4885
US-20080171747-A1 Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions QDPR, DHPS, DHODH SMN1; SMN2 4436/4885L3MBTL3 3917/4885L3MBTL1 3166/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885
US-20080293944-A1 Piperazinyl Compounds QDPR, DHPS, DPYD SMN1; SMN2 4327/4885L3MBTL3 4359/4885L3MBTL1 4364/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885L3MBTL3 1182/4885L3MBTL1 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.